Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380911/
https://www.ncbi.nlm.nih.gov/pubmed/28362441
http://dx.doi.org/10.1038/bcj.2017.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380911/
https://www.ncbi.nlm.nih.gov/pubmed/28362441
http://dx.doi.org/10.1038/bcj.2017.27

Ejemplares similares